A case of rofecoxib-associated stevens-johnson syndrome with corneal and conjunctival changes.
To report a case of rofecoxib (Vioxx)-associated Stevens-Johnson syndrome with corneal and conjunctival changes. Interventional case report. Case report of a 62-year-old woman with systemic lupus erythematosus (SLE) taking rofecoxib for arthritis for 3 weeks. Stevens-Johnson syndrome after 3 weeks of rofecoxib therapy. This case report suggests that oral rofecoxib may trigger Stevens-Johnson syndrome, potentially causing symblepharons, corneal neovascularization and cicatricial ectropions.